Trulicity® (dulaglutide) is now indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors or established cardiovascular disease
TORONTO, Sept. 22, 2020 (GLOBE NEWSWIRE) — On September 11, 2020, Health Canada approved Trulicity® (dulaglutide) to reduce the risk […]